do-me/EUR-LEX huggingface dataset:
Case C-473/23 P: Appeal brought on 24 July 2023 by Bimbo, SA against the judgment of the General Court (Second Chamber) delivered on 24 May 2023 in Case T-509/22, Bimbo v EUIPO — Bottari Europe (BimboBIKE)
Date: 2023-07-24
Institutions: Court of Justice
Subjects: EU trade mark, electric vehicle, electronic commerce, hand tool, polishing and scouring preparations, registered trade mark, spare part, toy industry, trade-mark law, two-wheeled vehicle








C_202400704EN.000101.fmx.xml












Official Journal of the European Union


EN
Series C













C/2024/704


22.1.2024





Appeal brought on 24 July 2023 by Bimbo, SA against the judgment of the General Court (Second Chamber) delivered on 24 May 2023 in Case T-509/22, Bimbo v EUIPO — Bottari Europe (BimboBIKE)
(Case C-473/23 P)
(C/2024/704)
Language of the case: English

Parties


Appellant: Bimbo, SA (represented by: J. Carbonell Callicó, abogado)

Other party to the proceedings: European Union Intellectual Property Office
By order of 7 November 2023, the Court of Justice (Chamber determining whether appeals may proceed) held that the appeal was not allowed to proceed and that the appellant should bear its own costs.


ELI: http://data.europa.eu/eli/C/2024/704/oj
ISSN 1977-091X (electronic edition)
Case T-256/23 R: Order of the President of the General Court of 24 July 2023 — Mylan Ireland v Commission (Interim relief — Medicinal products for human use — Marketing authorisation — Application for interim measures — Application for injunction — Lack of urgency)
Date: 2023-07-24
Institutions: General Court
Subjects: drug surveillance, generic drug, market approval








C_2023338EN.01002602.xml










25.9.2023   


EN


Official Journal of the European Union


C 338/26






Order of the President of the General Court of 24 July 2023 — Mylan Ireland v Commission
(Case T-256/23 R)
(Interim relief - Medicinal products for human use - Marketing authorisation - Application for interim measures - Application for injunction - Lack of urgency)
(2023/C 338/35)
Language of the case: English

Parties


Applicant: Mylan Ireland Ltd (Dublin, Ireland) (represented by: K. Roox, T. De Meese, J. Stuyck and C. Dumont, lawyers)

Defendant: European Commission (represented by: E. Mathieu, L. Haasbeek and A. Spina, acting as Agents)

Re:

By its application based on Articles 278 and 279 TFEU, the applicant seeks, in essence, first, suspension of operation of Commission Implementing Decision C(2023) 3067 final of 2 May 2023 amending Commission Implementing Decision C(2014) 601 final of 30 January 2014 granting marketing authorisation (‘MA’) for the medicinal product for human use Tecfidera — Dimethyl fumarate under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1), as amended, and any subsequent decision or act extending or replacing the contested decision in so far as they concern it, and, second, an injunction requiring the European Commission to refrain from taking any other measures which would amount to a withdrawal of the MA enjoyed by it or a prohibition on placing generic Dimethyl fumarate products on the market.

Operative part of the order







1.


The application for interim measures is dismissed.










2.


There is no longer any need to rule on the application to intervene submitted by Biogen Netherlands BV or on the application for confidential treatment submitted by Mylan Ireland Ltd.










3.


The costs relating to the proceedings for interim relief are reserved.










4.


Each party shall bear its own costs relating to the application to intervene submitted by Biogen Netherlands.
Case T-257/23 R: Order of the President of the General Court of 24 July 2023 — Neuraxpharm Pharmaceuticals v Commission (Interim relief — Medicinal products for human use — Marketing authorisation — Application for interim measures — Application for injunction — Lack of urgency)
Date: 2023-07-24
Institutions: General Court
Subjects: drug surveillance, generic drug, market approval








C_2023338EN.01002701.xml










25.9.2023   


EN


Official Journal of the European Union


C 338/27






Order of the President of the General Court of 24 July 2023 — Neuraxpharm Pharmaceuticals v Commission
(Case T-257/23 R)
(Interim relief - Medicinal products for human use - Marketing authorisation - Application for interim measures - Application for injunction - Lack of urgency)
(2023/C 338/36)
Language of the case: English

Parties


Applicant: Neuraxpharm Pharmaceuticals, SL (Barcelona, Spain) (represented by: K. Roox, T. De Meese, J. Stuyck and C. Dumont, lawyers)

Defendant: European Commission (represented by: E. Mathieu, L. Haasbeek and A. Spina, acting as Agents)

Re:

By its application based on Articles 278 and 279 TFEU, the applicant seeks, in essence, first, suspension of operation of Commission Implementing Decision C(2023) 3067 final of 2 May 2023 amending Commission Implementing Decision C(2014) 601 final of 30 January 2014 granting marketing authorisation (‘MA’) for the medicinal product for human use Tecfidera — Dimethyl fumarate under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1), as amended, and any subsequent decision or act extending or replacing the contested decision in so far as they concern it, and, second, an injunction requiring the European Commission to refrain from taking any other measures which would amount to a withdrawal of the MA enjoyed by it or a prohibition on placing generic Dimethyl fumarate products on the market.

Operative part of the order







1.


The application for interim measures is dismissed.










2.


There is no longer any need to rule on the application to intervene submitted by Biogen Netherlands BV or on the application for confidential treatment submitted by Neuraxpharm Pharmaceuticals, SL.










3.


The costs relating to the proceedings for interim relief are reserved.










4.


Each party shall bear its own costs relating to the application to intervene submitted by Biogen Netherlands.
Euro exchange rates (Source: reference exchange rate published by the ECB.) 21 July 2023 2023/C 260/04
Date: 2023-07-24
Institutions: European Commission
Subjects: euro, exchange rate, money








C_2023260EN.01000501.xml










24.7.2023   


EN


Official Journal of the European Union


C 260/5






Euro exchange rates (1)

21 July 2023
(2023/C 260/04)

1 euro =











 


Currency


Exchange rate




USD


US dollar


1,1123 




JPY


Japanese yen


157,63 




DKK


Danish krone


7,4508 




GBP


Pound sterling


0,86706 




SEK


Swedish krona


11,5517 




CHF


Swiss franc


0,9630 




ISK


Iceland króna


146,30 




NOK


Norwegian krone


11,1775 




BGN


Bulgarian lev


1,9558 




CZK


Czech koruna


24,062 




HUF


Hungarian forint


380,30 




PLN


Polish zloty


4,4583 




RON


Romanian leu


4,9367 




TRY


Turkish lira


29,9620 




AUD


Australian dollar


1,6510 




CAD


Canadian dollar


1,4668 




HKD


Hong Kong dollar


8,6946 




NZD


New Zealand dollar


1,7981 




SGD


Singapore dollar


1,4792 




KRW


South Korean won


1 429,52 




ZAR


South African rand


20,0385 




CNY


Chinese yuan renminbi


7,9860 




IDR


Indonesian rupiah


16 714,72 




MYR


Malaysian ringgit


5,0738 




PHP


Philippine peso


60,876 




RUB


Russian rouble


 




THB


Thai baht


38,230 




BRL


Brazilian real


5,3437 




MXN


Mexican peso


18,8531 




INR


Indian rupee


91,1750 






(1)  Source: reference exchange rate published by the ECB.
Case T-258/23 R: Order of the President of the General Court of 24 July 2023 — Zaklady Farmaceutyczne Polpharma v Commission (Interim relief — Medicinal products for human use — Marketing authorisation — Application for interim measures — Application for injunction — Lack of urgency)
Date: 2023-07-24
Institutions: General Court
Subjects: drug surveillance, generic drug, market approval








C_2023338EN.01002801.xml










25.9.2023   


EN


Official Journal of the European Union


C 338/28






Order of the President of the General Court of 24 July 2023 — Zaklady Farmaceutyczne Polpharma v Commission
(Case T-258/23 R)
(Interim relief - Medicinal products for human use - Marketing authorisation - Application for interim measures - Application for injunction - Lack of urgency)
(2023/C 338/37)
Language of the case: English

Parties


Applicant: Zaklady Farmaceutyczne Polpharma S.A. (Starogard Gdański, Poland) (represented by: K. Roox, T. De Meese, J. Stuyck and C. Dumont, lawyers)

Defendant: European Commission (represented by: E. Mathieu, L. Haasbeek and A. Spina, acting as Agents)

Re:

By its application based on Articles 278 and 279 TFEU, the applicant seeks, in essence, first, suspension of operation of Commission Implementing Decision C(2023) 3067 final of 2 May 2023 amending Commission Implementing Decision C(2014) 601 final of 30 January 2014 granting marketing authorisation (‘MA’) for the medicinal product for human use Tecfidera — Dimethyl fumarate (‘Tecfidera’) under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1), as amended, and any subsequent decision or act extending or replacing the contested decision in so far as they concern it, and, second, an injunction requiring the European Commission to refrain from taking any other measures which would amount to a withdrawal of the MA enjoyed by it or a prohibition on placing generic Dimethyl fumarate products on the market.

Operative part of the order







1.


The application for interim measures is dismissed.










2.


There is no longer any need to rule on the applications to intervene submitted by Biogen Netherlands BV and Biogaran SAS or on the applications for confidential treatment submitted by Zaklady Farmaceutyczne Polpharma S.A.










3.


The costs relating to the proceedings for interim relief are reserved.










4.


Each party shall bear its own costs relating to the applications to intervene submitted by Biogen Netherlands and Biogaran.
Joint statement of the European Parliament and of the Council 2023/C 260/01
Date: 2023-07-24
Institutions: Council of the European Union, European Parliament
Subjects: EU aid, EU financial instrument, EU production, European arms policy, European defence policy, arms industry, arms supply, common security and defence policy, firearms and munitions, security of supply








C_2023260EN.01000101.xml










24.7.2023   


EN


Official Journal of the European Union


C 260/1






Joint statement of the European Parliament and of the Council
(2023/C 260/01)
The European Parliament and the Council acknowledge the urgency of the need to help the European Defence Technological and Industrial Base (EDTIB) to ramp up production in the context of the challenges created by Russia’s unprovoked and unjustified war of aggression against Ukraine, and recall that the Regulation on supporting ammunition production (ASAP) provides an immediate response to that urgent need by putting in place a new temporary instrument to facilitate industrial investments.
The European Parliament and the Council stress the need to consider all appropriate measures to strengthen and develop the EDTIB, including small and medium-sized enterprises, and to remove obstacles and bottlenecks so as to allow the industry to produce more along the value chains.
The European Parliament and the Council therefore call on the Commission to consider, as appropriate, putting forward as soon as possible any further initiatives necessary to strengthen the EDTIB, including adequate financing, for instance in the context of the European Defence Investment Programme, as well as a legal framework aimed at ensuring security of supply and supporting ammunition production.
The European Parliament and the Council agree to examine any such initiatives without delay and in a spirit of mutual sincere cooperation.
Commission Implementing Regulation (EU) 2023/1571 of 24 July 2023 entering a name in the register of protected designations of origin and protected geographical indications (‘Българско бяло саламурено сирене/Bulgarsko byalo salamureno sirene’ (PDO))
Date: 2023-07-24
Institutions: Directorate-General for Agriculture and Rural Development, European Commission
Subjects: Bulgaria, cows’ milk cheese, designation of origin, goats’ milk cheese, labelling, product designation, sheep's milk cheese








L_2023192EN.01001101.xml










31.7.2023   


EN


Official Journal of the European Union


L 192/11








            COMMISSION IMPLEMENTING REGULATION (EU) 2023/1571
of 24 July 2023
         
entering a name in the register of protected designations of origin and protected geographical indications (‘Българско бяло саламурено сирене/Bulgarsko byalo salamureno sirene’ (PDO))


THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EU) No 1151/2012 of the European Parliament and of the Council of 21 November 2012 on quality schemes for agricultural products and foodstuffs (1), and in particular Article 52(2) thereof,

Whereas:







(1)


Pursuant to Article 50(2)(a) of Regulation (EU) No 1151/2012, Bulgaria’s application to register the name ‘Българско бяло саламурено сирене/Bulgarsko byalo salamureno sirene’ was published in the Official Journal of the European Union (2).












(2)


As no statement of opposition under Article 51 of Regulation (EU) No 1151/2012 has been received by the Commission, the name ‘Българско бяло саламурено сирене/Bulgarsko byalo salamureno sirene’ should therefore be entered in the register,





HAS ADOPTED THIS REGULATION:



Article 1
The name ‘Българско бяло саламурено сирене/Bulgarsko byalo salamureno sirene’ (PDO) is hereby entered in the register.
The name specified in the first paragraph denotes a product in Class 1.3. Cheeses, as listed in Annex XI to Commission Implementing Regulation (EU) No 668/2014 (3).


Article 2
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.




This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 24 July 2023.


For the Commission,


On behalf of the President,

Janusz WOJCIECHOWSKI
            

Member of the Commission






(1)  
            OJ L 343, 14.12.2012, p. 1.

(2)  
            OJ C 129, 13.4.2023, p. 67.

(3)  Commission Implementing Regulation (EU) No 668/2014 of 13 June 2014 laying down rules for the application of Regulation (EU) No 1151/2012 of the European Parliament and of the Council on quality schemes for agricultural products and foodstuffs (OJ L 179, 19.6.2014, p. 36).
Case T-278/23 R: Order of the President of the General Court of 24 July 2023 — Zentiva and Zentiva Pharma v Commission (Interim relief — Medicinal products for human use — Marketing authorisation — Application for interim measures — Application for injunction — Lack of urgency)
Date: 2023-07-24
Institutions: General Court
Subjects: drug surveillance, generic drug, market approval








C_2023338EN.01002901.xml










25.9.2023   


EN


Official Journal of the European Union


C 338/29






Order of the President of the General Court of 24 July 2023 — Zentiva and Zentiva Pharma v Commission
(Case T-278/23 R)
(Interim relief - Medicinal products for human use - Marketing authorisation - Application for interim measures - Application for injunction - Lack of urgency)
(2023/C 338/38)
Language of the case: English

Parties


Applicants: Zentiva k.s. (Prague, Czech Republic), Zentiva Pharma GmbH (Frankfurt am Main, Germany) (represented by: K. Roox, T. De Meese and J. Stuyck, lawyers)

Defendant: European Commission (represented by: E. Mathieu, L. Haasbeek and A. Spina, acting as Agents)

Re:

By their application based on Articles 278 and 279 TFEU, the applicants seek, in essence, first, suspension of operation of Commission Implementing Decision C(2023) 3067 final of 2 May 2023 amending Commission Implementing Decision C(2014) 601 final of 30 January 2014 granting marketing authorisation (‘MA’) for the medicinal product for human use Tecfidera — Dimethyl fumarate under Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ 2004 L 136, p. 1), as amended, and any subsequent decision or act extending or replacing the contested decision in so far as they concern them, and, second, an injunction requiring the European Commission to refrain from taking any other measures which would amount to a withdrawal of the MAs enjoyed by them or a prohibition on placing generic Dimethyl fumarate products on the market.

Operative part of the order







1.


The application for interim measures is dismissed.










2.


There is no longer any need to rule on the application to intervene submitted by Biogen Netherlands BV or on the application for confidential treatment submitted by Zentiva k.s. and Zentiva Pharma GmbH.










3.


The costs relating to the proceedings for interim relief are reserved.










4.


Each party shall bear its own costs relating to the application to intervene submitted by Biogen Netherlands.
Prior notification of a concentration (Case M.11171 – APOLLO MANAGEMENT / ARCONIC) Candidate case for simplified procedure (Text with EEA relevance) 2023/C 260/06
Date: 2023-07-24
Institutions: Directorate-General for Competition, European Commission
Subjects: aluminium, building industry, economic concentration, investment, investment company, merger control, metallurgical industry, plate, subsidiary








C_2023260EN.01000801.xml










24.7.2023   


EN


Official Journal of the European Union


C 260/8






Prior notification of a concentration
(Case M.11171 – APOLLO MANAGEMENT / ARCONIC)
Candidate case for simplified procedure
(Text with EEA relevance)
(2023/C 260/06)

1.   
On 14 July 2023, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


Arconic Corporation (‘Arconic’, US);










—


Arsenal AIC Parent LLC (‘Arsenal Parent’, US), an investment vehicle indirectly controlled by investment funds managed by affiliates of Apollo Management, L.P. (‘Apollo Management’), a subsidiary of Apollo Global Management, Inc. (‘Apollo’).




Apollo will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Arconic. The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


Apollo provides capital solutions to businesses and invests in all parts of the capital structure. Through its subsidiary Altermira, it is active in the manufacturing and supply of semi-finished aluminium products and extrusions,










—


Arconic produces aluminium products across three reporting segments, being aluminium flat rolled products, extrusions, and building and construction systems, serving customers mainly across the aerospace, automotive, commercial transportation, brazing and industrial industries.






3.   

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.



4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11171 – APOLLO MANAGEMENT / ARCONIC
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  OJ C 366, 14.12.2013, p. 5.